First Tracks Biotherapeutics Inc. Ordinary Shares (TRAX)
Stock · NASDAQ · Health Care
$34.48as of 10/16/2026
Price chart
Active signals
Support level
$16.7
Industry
Biotechnology: Pharmaceutical Preparations
About TRAX
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 104
- Website
- www.firsttracksbio.com
Fundamentals
- 1-day range
- $33.38$37.07
- Market cap
- $1.58B
- P/E (trailing)
- —
- P/E (forward)
- -9.62
- EPS (trailing)
- $-4.71
- Dividend yield
- —
- Beta
- 1.52
- Avg. volume
- 846.7K
52-week range
$14.72$49.91
Next earnings: November 5, 2026 · EPS estimate $-0.89
Forecasts
12 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$100
+190.0%
Median
$70
+103.0%
Low
$57
+65.3%
First Tracks Biotherapeutics Inc. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- AAPGAscentage Pharma Group International American Depository Shares$15.37▲ 4.63%Market cap $1.60BP/E —$27.12$75.1
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.29$20.18$72.36
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| AAPG Ascentage Pharma Group International American Depository Shares | $1.60B | — | $15.37 | ▲ 4.63% | $27.12$75.1 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.29 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Leerink Partners Maintains Outperform on First Tracks, Raises Price Target to $90benzinga · 10/16/2026
- Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50Benzinga · 9/30/2026
- AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?Yahoo · 9/26/2026
- This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · 9/18/2026
- Evercore ISI Group Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $65Benzinga · 9/18/2026
- Guggenheim Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $100Benzinga · 9/16/2026
Insider Activity
Insider Actions →Acquired
693.8K
Disposed
78.5K
- John A. Orwin · September 15, 2026 · Option Exercise1.3K
- J. Anthony Ware · September 2, 2026 · Option Exercise10.7K
- J. Anthony Ware · September 2, 2026 · Option Exercise28.6K
- J. Anthony Ware · September 2, 2026 · Sale39.3K @ $44.78
- J. Anthony Ware · September 2, 2026 · Option Exercise39.3K @ $5.74
- STONE BENJAMIN · August 15, 2026 · Grant60.5K
- Paul F. Lizzul · August 15, 2026 · Grant60.5K
- Daniel Faga · August 15, 2026 · Grant193.6K
- STONE BENJAMIN · August 2, 2026 · Grant60.5K
- Paul F. Lizzul · August 2, 2026 · Grant60.5K
- Daniel Faga · August 2, 2026 · Grant193.6K
- John P. Schmid · June 15, 2026 · Option Exercise6.0K
- John A. Orwin · June 15, 2026 · Option Exercise6.0K
- Dennis M. Fenton · June 15, 2026 · Option Exercise6.0K
- Magda Marquet · June 15, 2026 · Option Exercise6.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TRAX Announces $200M Private Placement and Analyst Upgrades
First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.
TRAX Announces $200M Private Placement and Analyst Upgrades. First Tracks Biotherapeutics announced a $200 million private placement of shares at $32.75 each to institutional investors. Following this capital raise and recent trial data for ANB033, several firms including Leerink Partners, Evercore ISI, and Canaccord Genuity raised their price targets. The stock currently trades within its 52-week range, with an average analyst target of $74.17.